Side-by-side · Research reference

MK-677vsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed13/45 cited

BFDA-ApprovedVerified15/53 cited

MK-677

Oral GHS · Ibutamoren

10–25 mgDaily dose (oral)Nass 2008

Phase 2Evidence levelMurphy 1998 Nass 2008

~24 hrHalf-lifeNass 2008

Oral capsule · 1×/day

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

MK-677

Semaglutide

Primary target

Ghrelin receptor (GHS-R1a)Murphy 1998

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

Pulsatile pattern preserved despite long half-lifeMurphy 1998

Glucose-dependent insulin release preserves physiological feedback

Origin

Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

MK-677

Semaglutide

Standard dose

10–25 mg / day oralNass 2008

25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.

—

Frequency

Once daily, oral

Once weekly, same day each week

Lower / starter dose

5 mg / day

—

Evidence basis

Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008 Murphy 1998

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Duration

8–16 weeks per cycle (off-cycle to reset receptor sensitivity)

Indefinite for chronic indication

Discontinuation results in weight regain.

Reconstitution

Oral, no reconstitution

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Timing

Pre-sleep preferred for natural GH pulse alignment

Any time of day, with or without food

Half-life

~24 hrNass 2008

Once-daily dosing covers 24 hours.

~7 days (168 h)WEGOVY (semaglutide) injection 2021

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

04Side Effects & Safety

Parameter

MK-677

Semaglutide

Increased appetite

Strong appetite increase via ghrelin agonism

—

Water retention

Mild edema, paresthesias

—

Glucose tolerance

↑ HbA1c +0.3–0.5% in 2-yr elderly trialNass 2008

—

IGF-1 elevation

+50–100% sustainedNass 2008

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Cardiovascular

No clear adverse signal in trials; congestive heart failure caution

—

Drowsiness

Common, especially during initial weeks

—

Pregnancy / OB

Avoid

ContraindicatedWEGOVY (semaglutide) injection 2021

GI symptoms

—

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

MK-677

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis
·Congestive heart failure (caution)

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

MK-677

·Untreated diabetes
·Pre-diabetes
·Severe insulin resistance

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

MK-677

Semaglutide

1. Form

Capsule or oral solution. No injection.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Site

Oral. Take with or without food.

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Timing

Pre-sleep preferred — aligns with natural GH pulse.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Storage

Capsule: room temp ≤25 °C, dry place.

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Caveat

Monitor HbA1c every 8–12 weeks during chronic use.

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

MK-677

— no documented stacks

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)